STAT-C: New therapies cannot get here fast enough

[1]  K. Kossen,et al.  936 COMBINATION OF THE NS3/4A PROTEASE INHIBITOR ITMN-191 WITH THE ALLOSTERIC NS5B POLYMERASE INHIBITOR ITMN-8020 ENHANCES REPLICON CLEARANCE AND REDUCES THE EMERGENCE OF DRUG RESISTANT VARIANTS , 2009 .

[2]  Todd M. Allen,et al.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment‐naïve patients , 2008, Hepatology.

[3]  G. Everson,et al.  R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin , 2008, Hepatology.

[4]  E. Keeffe,et al.  68 RANDOMIZED CONTROLLED TRIAL OF NITAZOXANIDE-PEGINTERFERON-RIBAVIRIN, NITAZOXANIDE-PEGINTERFERON AND PEGINTERFERON-RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 4 , 2008 .

[5]  P. Marcellin,et al.  805 HCV-RNA STATUS AT WEEK 12 OF TREATMENT WITH PEGINTERFERON ALFA-2A/RBV PREDICTS SVR IN PATIENTS WITH PRIOR NON-RESPONSE TO PEGYLATED INTERFERON ALFA-2B/RBV: RESULTS FROM REPEAT STUDY , 2008 .

[6]  G. Everson,et al.  66 POTENT ANTIVIRAL ACTIVITY OF THE HCV NUCLEOSIDE POLYMERASE INHIBITOR R7128 WITH PEG-IFN AND RIBAVIRIN: INTERIM RESULTS OF R7128 500MG BID FOR 28 DAYS , 2008 .

[7]  R. Schooley,et al.  3-drug synergistic interactions of small molecular inhibitors of hepatitis C virus replication. , 2008, The Journal of infectious diseases.

[8]  J. Murray,et al.  Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations , 2007, Hepatology.

[9]  Tara L. Kieffer,et al.  Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients , 2007, Hepatology.

[10]  Lisa I. Backus,et al.  Predictors of response of U.S. veterans to treatment for the hepatitis C virus , 2007 .

[11]  M. Biselli,et al.  A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C , 2007, Journal of Gastroenterology.

[12]  Tara L. Kieffer,et al.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. , 2007, Gastroenterology.

[13]  K. Shimotohno,et al.  Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. , 2005, Molecular cell.

[14]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[15]  K. Reddy,et al.  Peginterferon alfa‐2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1 , 2004, Hepatology.

[16]  P. Killenberg,et al.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. , 2004, The New England journal of medicine.

[17]  William M. Lee,et al.  Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. , 2004, Gastroenterology.

[18]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[19]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .